Targeting apoptosis using the B-cell lymphoma-2 (BCL-2) inhibitor venetoclax is a promising novel therapeutic approach for MCL, with overall response rates (ORR) of 50–75% in early clinical trials, depending upon the number and the type of pretreatments the patients received. Here, BCL2 is linked to mantle cell lymphoma.